BLOOMBERG NEWS -- New York Times
Genentech’s plan to restrict the availability of Avastin so doctors cannot use it instead of a more expensive medicine for eye disease will cost taxpayers
$1 billion to $3 billion a year, according to Senator Herb Kohl.